Kelly Elise Dooley MD

Professor of Medicine, Vanderbilt University Medical Center

1161 21st Avenue South, A2200 MCNNashville, TN 37232
Phone+1 615-322-8972

Dr. Dooley is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dooley's full profile Already have an account?

Summary

Kelly Dooley, MD is a healthcare professional specialized in Infectious Diseases and based in Nashville, TN. Her education included a Fellowship in Infectious Diseases and Residency in Internal Medicine at Johns Hopkins University after graduating from Duke University School of Medicine. Dr. Dooley has experience in emerging infectious diseases and has published in a number of respected journals on topics related to infectious diseases, particularly tuberculosis and HIV. Her work in clinical trials reflects her focus on the study and treatment of tuberculosis.

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OR State Medical License 2002 - Present
RI State Medical License 2026 - 2028
TN State Medical License 2022 - 2027
MD State Medical License 2006 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
COMPLETED
PHASE1
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
COMPLETED
PHASE1
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
COMPLETED
PHASE1

Publications & Presentations

PubMed

2 citations
Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.
Agathe Béranger, Belén P Solans, Ryo Miyakawa, Helen McIlleron, Joel Tarning
The European Respiratory Journal. 2026-03-01
11 citations
A clinical practice guideline for tuberculous meningitis.
Joseph Donovan, Fiona V Cresswell, Elizabeth W Tucker, Angharad G Davis, Ursula K Rohlwink
The Lancet. Infectious Diseases. 2026-02-01
Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.
Spencer C Darveau, Sharan Yadav, Kelly E Dooley, Jyoti S Mathad
Infection and Drug Resistance. 2026-01-01

Journal Articles

State of the Art Review of HIV‐TB Coinfection in Special Populations
Ethel D Weld, Kelly E Dooley, Clinical Pharmacology & Therapeutics

Press Mentions

VUMC’s Kelly Dooley Joins Clinical Pharmacology BoardJanuary 13th, 2025
Johns Hopkins School of Medicine Among Clinical Trial Sites Testing COVID-19 TherapiesNovember 18th, 2020
Johns Hopkins Researchers to Present Latest Findings on TB and HIV at CROI 2019March 7th, 2019

Grant Support

Short-course rifapentine for TB prevention for all: clinical pharmacology mattersVANDERBILT UNIVERSITY MEDICAL CENTER2024–2029
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchVANDERBILT UNIVERSITY MEDICAL CENTER2020–2026
Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV)VANDERBILT UNIVERSITY MEDICAL CENTER2023–2025
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025